Hyperpolarized MR Imaging with Carbon-13 Pyruvate for Heart and Cardiometabolic Diseases in Adults

What this Trial Is About

Researchers are exploring a new imaging technique called carbon-13 (13C) magnetic resonance imaging (MRI) to better understand metabolism in the body. Unlike the usual PET scans with 18F fluorodeoxyglucose (FDG), which show glucose uptake but not metabolic changes down the line, this method uses hyperpolarized 13C-pyruvate to enhance MRI signals dramatically. The study aims to assess the feasibility and usefulness of this approach in healthy volunteers and patients with cardiovascular or cardiometabolic diseases. In this study, participants will receive an intravenous injection of hyperpolarized 13C-pyruvate at a dose of 0.43 mL per kilogram of body weight. The injection is given at a rate of 5 mL per second, followed by a saline flush, all while inside an MRI scanner. This procedure is designed to capture rapid metabolic processes by acquiring high-quality images within a short time frame because the enhanced signal from hyperpolarization lasts only 1 to 2 minutes. The study will establish reference ranges for metabolic products in healthy volunteers and develop applications for patients with heart and metabolic diseases. Participants will be involved in imaging sessions lasting about 30 to 45 minutes after the injection to assess the reproducibility and feasibility of the imaging technique. Researchers will monitor metabolic activity through the MRI scans and analyze outcomes related to the imaging process itself. The study includes healthy volunteers and patients with diagnosed cardiovascular or cardiometabolic conditions. Safety will be monitored throughout, and participants will be asked to comply with study procedures and provide informed consent. The total duration for participation depends on individual scheduling but centers around the imaging session and follow-up for data collection.

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body